Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Key claim: A first-in-human phase I dose-escalation trial of ZE74-0282, an experimental drug targeting JAK2 V617F-positive blood cancers, is underway to evaluate safety, tolerability, pharmacokinetics, and early anti-tumor activity.
Abstract
This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F. The main goals are to find the right dose level, to see how safe and tolerable different doses are, how the drug moves through the body, and whether it shows early signs of anti-tumor activity. Participants will receive ZE74-0282 in one of several dose groups. The study is open-label, meaning both the doctor and the participant know which treatment is given. It will take place at multiple centers across different countries. Blood tests and regular check-ups will be done to monitor side effects and measure the effect on the disease.
Why this matters
ZE74-0282 represents a novel investigational agent specifically targeting JAK2 V617F-mutant blood cancers, potentially expanding the MPN therapeutic arsenal beyond current type I JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) that inhibit both wild-type and mutant JAK2. If ZE74-0282 achieves mutant-selective activity, it could parallel the rationale behind type II JAK2 inhibitors like AJ1-11095 and offer improved therapeutic index. The phase I dose-escalation will provide initial human safety and PK data to determine whether this mechanism warrants further development.